Oric Pharmaceuticals Selects Phase 3 Dose for Rinzimetostat, Plans Pivotal Trial in Prostate Cancer

summarizeSummary

Oric Pharmaceuticals reported strong Phase 1b data for rinzimetostat, selecting a Phase 3 dose and confirming plans to initiate a pivotal trial in prostate cancer in 1H 2026.

check_boxKey Events

• Rinzimetostat Phase 3 Dose Selected

  The company selected 400 mg QD of rinzimetostat in combination with darolutamide as the Recommended Phase 3 Dose (RP3D) for its lead prostate cancer candidate, based on lower toxicity and comparable efficacy.

• Positive Phase 1b Data Reported

  Dose optimization data from the Phase 1b trial showed a differentiated safety profile and competitive efficacy (rPFS, PSA, ctDNA) for rinzimetostat in mCRPC patients, comparing favorably to competitor regimens.

• Global Phase 3 Trial Planned

  Oric Pharmaceuticals plans to initiate the global Phase 3 Himalayas-1 study in post-abiraterone mCRPC in the first half of 2026, advancing rinzimetostat towards potential registration.

• Strong Commercial Potential

  The company highlighted a significant addressable market in post-abiraterone mCRPC, with independent market research suggesting best-in-class potential for rinzimetostat.

auto_awesomeAnalysis

Oric Pharmaceuticals announced positive dose optimization data from its Phase 1b trial of rinzimetostat (ORIC-944), a PRC2 inhibitor for metastatic castration-resistant prostate cancer (mCRPC). The company selected 400 mg QD in combination with darolutamide as the Recommended Phase 3 Dose (RP3D), citing a differentiated safety profile and competitive efficacy compared to other therapies. This data supports the planned initiation of the global Phase 3 Himalayas-1 trial in post-abiraterone mCRPC in the first half of 2026, marking a significant advancement for its lead oncology candidate.